Table 4.
Prognostic factors for overall survival in multivariate analysis (n=65)
| Variable | Overall survival (95% CI, mo) | Univariate p-value | Multivariate p-value | Hazard ratio (95% CI) | |
|---|---|---|---|---|---|
| Gender | Male | 18.73 (14.43-23.03) | 0.856 | - | - |
| Female | 19.33 (13.06-25.60) | ||||
| Age (yr) | ≤ 65 | 18.37 (14.79-21.95) | 0.278 | - | - |
| > 65 | 22.57 (13.15-31.99) | ||||
| Disease status | Metastatic | 19.63 (15.35-23.91) | 0.973 | - | - |
| Recurrent | 17.03 (16.30-17.76) | ||||
| Location | Right | 19.53 (14.51-24.54) | 0.742 | - | - |
| Left | 18.37 (13.99-22.75) | ||||
| No. of metastatic sites | 0-1 | 31.60 (13.69-49.51) | 0.075 | - | - |
| ≥ 2 | 18.73 (15.30-22.16) | ||||
| Liver metastasis | Yes | 16.97 (14.01-19.93) | 0.033 | 0.038 | 1.940 (1.039-3.624) |
| No | 31.60 (22.74-40.46) | ||||
| Debulking operation | Yes | 25.67 (19.02-32.32) | 0.014 | 0.019 | 2.023 (1.123-3.642) |
| No | 16.20 (12.01-20.386) | ||||
| Platelet (x103 μL) | ≤ 150 | 3.87 (NA) | 0.551 | - | - |
| > 150 | 19.33 (16.07-22.59) | ||||
| Hemoglobin (g/dL) | ≤ 11.7 | 18.73 (14.67-22.79) | 0.459 | - | - |
| > 11.7 | 19.33 (14.91-23.75) | ||||
| Albumin (g/dL) | ≤ 3.2 | 22.57 (15.36-29.78) | 0.616 | - | - |
| > 3.2 | 18.37 (15.49-21.26) | ||||
| CA 19-9 (IU/mL) | ≤ 37 | 20.90 (12.82-28.98) | 0.036 | 0.307 | 1.365 (0.752-2.476) |
| > 37 | 16.67 (9.79-23.55) | ||||
| Serum KRAS | Mutant | 17.03 (9.50-24.56) | 0.991 | - | - |
| Wild type | 19.63 (16.06-23.20) | ||||
| Tissue KRAS | Mutant | 17.03 (13.62-20.44) | 0.305 | - | - |
| Wild type | 20.90 (11.70-30.09) | ||||
| Second or more line | Yes | 19.53 (15.90-23.16) | 0.820 | - | - |
| No | 16.97 (0-38.20) | ||||
CI, confidence interval; CA 19-9, cancer antigen 19-9; NA, not available.